Provided by Tiger Trade Technology Pte. Ltd.

Atara Biotherapeutics

6.29
-0.3900-5.84%
Volume:644.22K
Turnover:4.16M
Market Cap:45.35M
PE:2.87
High:7.05
Open:6.45
Low:6.05
Close:6.68
52wk High:19.15
52wk Low:3.92
Shares:7.21M
Float Shares:4.61M
Volume Ratio:0.46
T/O Rate:13.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.19
EPS(LYR):-11.4053
ROE:-2014.86%
ROA:30.86%
PB:-1.24
PE(LYR):-0.55

Loading ...

FDA says unable to approve Atara Biotherapeutics Ebvallo BLA in present form

TIPRANKS
·
Jan 12

BUZZ-Atara Biotherapeutics sinks as FDA rejects cancer drug application

Reuters
·
Jan 12

BRIEF-Pierre Fabre Pharmaceuticals On Jan 9, Got Complete Response Letter For Tabelecleucel BLA From U.S. FDA

Reuters
·
Jan 12

Pierre Fabre: in New Crl, FDA Said It No Longer Considers Previously Accepted Single-Arm Allele Study to Be Enough to Support Accelerated Approval

THOMSON REUTERS
·
Jan 12

US FDA declines to approve Atara's therapy for rare blood cancer

Reuters
·
Jan 12

BRIEF-Atara Biotherapeutics Provides Regulatory And Business Update On Ebvallo™ (Tabelecleucel)

Reuters
·
Jan 12

Atara Biotherapeutics Slashes Workforce by 90 Percent

Reuters
·
Jan 12

Atara Biotherapeutics Inc - FDA Unable to Approve Ebvallo Bla in Present Form

THOMSON REUTERS
·
Jan 12

Atara Biotherapeutics Inc - FDA Issues Complete Response Letter for Ebvallo Bla

THOMSON REUTERS
·
Jan 12

Atara Biotherapeutics Inc: U.S. Food and Drug Administration Has Issued a Complete Response Letter (Crl)

THOMSON REUTERS
·
Jan 12

Atara Biotherapeutics Provides Regulatory and Business Update on Ebvallo™ (Tabelecleucel)

THOMSON REUTERS
·
Jan 12

Atara Biotherapeutics Stock (ATRA) Jumps as FDA Decision on Viral Therapy Nears

TIPRANKS
·
Jan 08

BRIEF-Atara Biotherapeutics Inc - Entered Fourth Amendment With Pierre Fabre - SEC Filing

Reuters
·
Jan 03

Atara Biotherapeutics Inc - Milestone Payments Reduced From $40 Mln to $31 Mln - SEC Filing

THOMSON REUTERS
·
Jan 03

Atara Biotherapeutics Amends Pierre Fabre Agreement to Adjust Milestone Payments

Reuters
·
Jan 03

Atara Biotherapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Dec 19, 2025

Atara Biotherapeutics Inc : Mizuho Raises Target Price to $18 From $16

THOMSON REUTERS
·
Nov 21, 2025

Atara Biotherapeutics price target raised to $18 from $16 at Mizuho

TIPRANKS
·
Nov 21, 2025

Top Executives Make Significant Moves with Atara Biotherapeutics Stock!

TIPRANKS
·
Nov 20, 2025

Atara Biotherapeutics Chief Accounting Officer Yanina Grant-Huerta Reports Disposal of Common Shares

Reuters
·
Nov 20, 2025